Literature DB >> 8640677

Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?

G Raviv1, A R Zlotta, T h Janssen, F Descamps, J P Vanegas, A Verhest, C C Schulman.   

Abstract

BACKGROUND: Prostatic intraepithelial neoplasia (PIN) is considered to be a precursor of prostate carcinoma in which serum levels of prostate specific antigen (PSA) have been correlated with PIN grades. The aim of this study was to determine whether PSA and prostate specific antigen density (PSAD), obtained at the time of initial diagnosis of PIN without concurrent carcinoma, can be used as predictive factors to discriminate patients with subsequent cancer on repeat biopsy.
METHODS: We studied, retrospectively, the records of 93 patients with PIN (low and high grade) without concurrent carcinoma at the time of their first needle biopsy. We assessed the relationship between initial PIN grade, PSA, and PSAD with later detection of carcinoma on repeat biopsy. Patients were divided into 3 subgroups for analysis according to their initial PSA level (0-4, 4.1-10, >10 ng/mL).
RESULTS: Carcinoma detection rate on repeat biopsy was 13.3% for patients with low grade PIN and 47.7% for patients with high grade PIN (P < 0.006). High grade PIN was frequently associated with subsequent carcinoma whatever the PSA level (33.3-61.9%). Low grade PIN was associated with subsequent carcinoma in 42.8% of the cases when PSA was greater than 10 ng/mL. When PSA was between 4 and 10 ng/mL, low grade PIN carcinoma was found on repeat biopsies in only 10.7% of the cases (P = 0.05). In none of the PSA subgroups did PSAD enhance later cancer detection.
CONCLUSIONS: For patients with high grade PIN, the incidence of subsequent carcinoma is high, whatever the PSA values. For these cases repeat biopsies should be recommended. Patients with low grade PIN and PSA greater than 10 ng/mL should have repeat biopsies because the incidence of subsequent carcinoma is high and comparable to high grade PIN. PSAD did not provide additional information.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640677     DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2103::AID-CNCR21>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

Review 2.  Biopsy standards for detection of prostate cancer.

Authors:  Bob Djavan; Markus Margreiter
Journal:  World J Urol       Date:  2007-03-07       Impact factor: 4.226

3.  High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.

Authors:  Nermina Obralic; Benjamin Kulovac
Journal:  Bosn J Basic Med Sci       Date:  2011-11       Impact factor: 3.363

4.  Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.

Authors:  A L Woynarowska BAHigdon; R M Muñoz; P Bushong; S J Waters
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 5.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance.

Authors:  R Montironi; R Mazzucchelli; F Algaba; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

6.  Radical prostatectomy for high grade prostatic intraepithelial neoplasia.

Authors:  R Woderich; J McLoughlin; S Deen
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 7.  [Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].

Authors:  J Palisaar; T Eggert; M Graefen; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.